Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 221

1.

Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia.

Fernandez HH, Stamler D, Davis MD, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Woods SW, Bega D, LeDoux MS, Shprecher DR, Anderson KE.

J Neurol Neurosurg Psychiatry. 2019 Jul 10. pii: jnnp-2018-319918. doi: 10.1136/jnnp-2018-319918. [Epub ahead of print]

2.

Clinical features and subtypes of restless legs syndrome in Chinese population: a study of 359 patients.

Zhu XY, Wu TT, Wang HM, Ni LY, Li X, Liu Y, Zhang XJ, Chen YJ, Cui XX, Ondo WG, Wu YC.

Sleep Med. 2019 Jul;59:15-23. doi: 10.1016/j.sleep.2019.01.053. Epub 2019 Mar 11.

PMID:
31153012
3.

Restless legs syndrome in end stage renal disease patients undergoing hemodialysis.

Lin XW, Zhang JF, Qiu MY, Ni LY, Yu HL, Kuo SH, Ondo WG, Yu Q, Wu YC.

BMC Neurol. 2019 Mar 29;19(1):47. doi: 10.1186/s12883-019-1265-y.

4.

46 Confirmed Safety of Deutetrabenazine for Tardive Dyskinesia in a 2-Year Open-label Extension Study.

Fernandez HH, Stamler D, Davis MD, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Woods SW, LeDoux MS, Shprecher DR, Anderson KE.

CNS Spectr. 2019 Feb;24(1):201. doi: 10.1017/S1092852919000397.

PMID:
30859974
5.

45 Long-term Treatment with Deutetrabenazine Is Associated with Continued Improvement in Tardive Dyskinesia: Results from an Open-label Extension Study.

Hauser RA, Fernandez HH, Stamler D, Davis MD, Factor SA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Woods SW, LeDoux MS, Shprecher DR, Anderson KE.

CNS Spectr. 2019 Feb;24(1):200-201. doi: 10.1017/S1092852919000385.

PMID:
30859973
6.

Systematic Literature Review of Quetiapine for the Treatment of Psychosis in Patients With Parkinsonism.

Chen JJ, Hua H, Massihi L, Portillo I, Alipour A, Ondo W, Dashtipour K.

J Neuropsychiatry Clin Neurosci. 2019 Summer;31(3):188-195. doi: 10.1176/appi.neuropsych.18080180. Epub 2019 Mar 8.

7.

Clinical and radiological characteristics of restless legs syndrome following acute lacunar infarction.

Tuo H, Tian Z, Ma X, Cui Y, Xue Y, Che J, Xu C, Chen K, Zhang Y, Zhang L, Bi H, Le W, Ondo W.

Sleep Med. 2019 Jan;53:81-87. doi: 10.1016/j.sleep.2018.06.004. Epub 2018 Jun 26.

PMID:
30458382
8.

Conversion of L-dopa to Extended Release L-dopa (Rytary®) in Patients with Fluctuating Parkinson's Disease: Predictors of Dose.

Ondo W, Coss P, Christie M, Pascual B.

J Parkinsons Dis. 2019;9(1):153-156. doi: 10.3233/JPD-181427.

PMID:
30400106
9.

Comparison of the Fahn-Tolosa-Marin Clinical Rating Scale and the Essential Tremor Rating Assessment Scale.

Ondo W, Hashem V, LeWitt PA, Pahwa R, Shih L, Tarsy D, Zesiewicz T, Elble R.

Mov Disord Clin Pract. 2017 Nov 23;5(1):60-65. doi: 10.1002/mdc3.12560. eCollection 2018 Jan-Feb.

10.

In Reply-Additional Safety Considerations Before Prescribing Opioids to Manage Restless Legs Syndrome.

Silber MH, Becker PM, Buchfuhrer MJ, Earley CJ, Ondo WG, Walters AS, Winkelman JW.

Mayo Clin Proc. 2018 Jul;93(7):955-956. doi: 10.1016/j.mayocp.2018.03.021. No abstract available.

PMID:
29976378
11.

Restless Legs Syndrome "Patient Odyssey" survey of disease burden on patient and spouses/partners.

Ondo W.

Sleep Med. 2018 Jul;47:51-53. doi: 10.1016/j.sleep.2017.12.003. Epub 2017 Dec 20.

PMID:
29753925
12.

Non-VMAT2 inhibitor treatments for the treatment of tardive dyskinesia.

Lin CC, Ondo WG.

J Neurol Sci. 2018 Jun 15;389:48-54. doi: 10.1016/j.jns.2018.02.014. Epub 2018 Feb 5. Review.

PMID:
29433806
13.

Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report.

Allen RP, Picchietti DL, Auerbach M, Cho YW, Connor JR, Earley CJ, Garcia-Borreguero D, Kotagal S, Manconi M, Ondo W, Ulfberg J, Winkelman JW; International Restless Legs Syndrome Study Group (IRLSSG).

Sleep Med. 2018 Jan;41:27-44. doi: 10.1016/j.sleep.2017.11.1126. Epub 2017 Nov 24.

14.

Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis.

Panchal SC, Ondo WG.

Curr Psychiatry Rep. 2018 Jan 27;20(1):3. doi: 10.1007/s11920-018-0869-z. Review.

PMID:
29374325
15.

Onabotulinum toxin-A injections for sleep bruxism: A double-blind, placebo-controlled study.

Ondo WG, Simmons JH, Shahid MH, Hashem V, Hunter C, Jankovic J.

Neurology. 2018 Feb 13;90(7):e559-e564. doi: 10.1212/WNL.0000000000004951. Epub 2018 Jan 17.

PMID:
29343468
16.

A 500 U/2 mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystonia.

Lew MF, Brashear A, Dashtipour K, Isaacson S, Hauser RA, Maisonobe P, Snyder D, Ondo W.

Int J Neurosci. 2018 Jul;128(7):619-626. doi: 10.1080/00207454.2017.1406935. Epub 2018 Jan 17.

PMID:
29343142
17.

The Appropriate Use of Opioids in the Treatment of Refractory Restless Legs Syndrome.

Silber MH, Becker PM, Buchfuhrer MJ, Earley CJ, Ondo WG, Walters AS, Winkelman JW; Scientific and Medical Advisory Board, Restless Legs Syndrome Foundation.

Mayo Clin Proc. 2018 Jan;93(1):59-67. doi: 10.1016/j.mayocp.2017.11.007.

PMID:
29304922
18.

Clinical features of Parkinson's disease with and without rapid eye movement sleep behavior disorder.

Liu Y, Zhu XY, Zhang XJ, Kuo SH, Ondo WG, Wu YC.

Transl Neurodegener. 2017 Dec 21;6:35. doi: 10.1186/s40035-017-0105-5. eCollection 2017.

19.

Restless Legs Syndrome: clinical features, diagnosis and a practical approach to management.

Wijemanne S, Ondo W.

Pract Neurol. 2017 Dec;17(6):444-452. doi: 10.1136/practneurol-2017-001762. Epub 2017 Nov 2. Review.

PMID:
29097554
20.

Restless legs syndrome secondary to pontine infarction: Clinical analysis of five cases.

Tuo HZ, Tian ZL, Cui YN, Ma XY, Xu CL, Bi HY, Zhang LY, Zhang YB, Le WD, Ondo W.

Chronic Dis Transl Med. 2017 Sep 1;3(3):186-190. doi: 10.1016/j.cdtm.2017.08.001. eCollection 2017 Sep.

21.

Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: a meta-analysis.

Schormair B, Zhao C, Bell S, Tilch E, Salminen AV, Pütz B, Dauvilliers Y, Stefani A, Högl B, Poewe W, Kemlink D, Sonka K, Bachmann CG, Paulus W, Trenkwalder C, Oertel WH, Hornyak M, Teder-Laving M, Metspalu A, Hadjigeorgiou GM, Polo O, Fietze I, Ross OA, Wszolek Z, Butterworth AS, Soranzo N, Ouwehand WH, Roberts DJ, Danesh J, Allen RP, Earley CJ, Ondo WG, Xiong L, Montplaisir J, Gan-Or Z, Perola M, Vodicka P, Dina C, Franke A, Tittmann L, Stewart AFR, Shah SH, Gieger C, Peters A, Rouleau GA, Berger K, Oexle K, Di Angelantonio E, Hinds DA, Müller-Myhsok B, Winkelmann J; 23andMe Research Team; DESIR study group.

Lancet Neurol. 2017 Nov;16(11):898-907. doi: 10.1016/S1474-4422(17)30327-7. Review.

22.

Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.

Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isojärvi J, Jarskog LF, Jimenez-Shahed J, Kumar R, McEvoy JP, Ochudlo S, Ondo WG, Fernandez HH.

Lancet Psychiatry. 2017 Aug;4(8):595-604. doi: 10.1016/S2215-0366(17)30236-5. Epub 2017 Jun 28.

PMID:
28668671
23.

Thalamic deep brain stimulation for orthostatic tremor: A multicenter international registry.

Merola A, Fasano A, Hassan A, Ostrem JL, Contarino MF, Lyons M, Krauss JK, Wolf ME, Klassen BT, van Rootselaar AF, Regidor I, Duker AP, Ondo W, Guridi J, Volkmann J, Wagle Shukla A, Mandybur GT, Okun MS, Witt K, Starr PA, Deuschl G, Espay AJ.

Mov Disord. 2017 Aug;32(8):1240-1244. doi: 10.1002/mds.27082. Epub 2017 Jun 20.

PMID:
28631862
24.

Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study.

Fernandez HH, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Meltzer HY, Woods SW, Bega D, LeDoux MS, Shprecher DR, Davis C, Davis MD, Stamler D, Anderson KE.

Neurology. 2017 May 23;88(21):2003-2010. doi: 10.1212/WNL.0000000000003960. Epub 2017 Apr 26.

25.

Psychiatric associations of adult-onset focal dystonia phenotypes.

Berman BD, Junker J, Shelton E, Sillau SH, Jinnah HA, Perlmutter JS, Espay AJ, Jankovic J, Vidailhet M, Bonnet C, Ondo W, Malaty IA, Rodríguez R, McDonald WM, Marsh L, Zurowski M, Bäumer T, Brüggemann N.

J Neurol Neurosurg Psychiatry. 2017 Jul;88(7):595-602. doi: 10.1136/jnnp-2016-315461. Epub 2017 Apr 24.

26.

Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy.

Espay AJ, Pagan FL, Walter BL, Morgan JC, Elmer LW, Waters CH, Agarwal P, Dhall R, Ondo WG, Klos KJ, Silver DE.

Neurol Clin Pract. 2017 Feb;7(1):86-93. doi: 10.1212/CPJ.0000000000000316. Review.

27.

Apomorphine Subcutaneous Injection for the Management of Morning Akinesia in Parkinson's Disease.

Isaacson S, Lew M, Ondo W, Hubble J, Clinch T, Pagan F.

Mov Disord Clin Pract. 2017 Jan-Feb;4(1):78-83. doi: 10.1002/mdc3.12350. Epub 2016 May 25.

28.

Deep brain stimulation (DBS) for severe restless legs syndrome: therapeutic and physiologic considerations.

Ondo W.

Sleep Med. 2017 Mar;31:93-94. doi: 10.1016/j.sleep.2016.04.005. Epub 2016 Jun 21. No abstract available.

PMID:
27964862
29.

Practice guideline summary: Treatment of restless legs syndrome in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Winkelman JW, Armstrong MJ, Allen RP, Chaudhuri KR, Ondo W, Trenkwalder C, Zee PC, Gronseth GS, Gloss D, Zesiewicz T.

Neurology. 2016 Dec 13;87(24):2585-2593. Epub 2016 Nov 16.

30.

Knowledge gaps and research recommendations for essential tremor.

Hopfner F, Haubenberger D, Galpern WR, Gwinn K, Van't Veer A, White S, Bhatia K, Adler CH, Eidelberg D, Ondo W, Stebbins GT, Tanner CM, Helmich RC, Lenz FA, Sillitoe RV, Vaillancourt D, Vitek JL, Louis ED, Shill HA, Frosch MP, Foroud T, Kuhlenbäumer G, Singleton A, Testa CM, Hallett M, Elble R, Deuschl G.

Parkinsonism Relat Disord. 2016 Dec;33:27-35. doi: 10.1016/j.parkreldis.2016.10.002. Epub 2016 Oct 4. Review.

31.

Clinical and demographic characteristics related to onset site and spread of cervical dystonia.

Norris SA, Jinnah HA, Espay AJ, Klein C, Brüggemann N, Barbano RL, Malaty IA, Rodriguez RL, Vidailhet M, Roze E, Reich SG, Berman BD, LeDoux MS, Richardson SP, Agarwal P, Mari Z, Ondo WG, Shih LC, Fox SH, Berardelli A, Testa CM, Cheng FC, Truong D, Nahab FB, Xie T, Hallett M, Rosen AR, Wright LJ, Perlmutter JS.

Mov Disord. 2016 Dec;31(12):1874-1882. doi: 10.1002/mds.26817. Epub 2016 Oct 18.

32.

Depth and Distribution of Symptoms in Restless Legs Syndrome/ Willis-Ekbom Disease.

Yeh P, Ondo WG, Picchietti DL, Poceta JS, Allen RP, Davies CR, Wang L, Shi Y, Bagai K, Walters AS.

J Clin Sleep Med. 2016 Dec 15;12(12):1669-1680. doi: 10.5664/jcsm.6356.

33.

A Randomized Trial of Focused Ultrasound Thalamotomy for Essential Tremor.

Elias WJ, Lipsman N, Ondo WG, Ghanouni P, Kim YG, Lee W, Schwartz M, Hynynen K, Lozano AM, Shah BB, Huss D, Dallapiazza RF, Gwinn R, Witt J, Ro S, Eisenberg HM, Fishman PS, Gandhi D, Halpern CH, Chuang R, Butts Pauly K, Tierney TS, Hayes MT, Cosgrove GR, Yamaguchi T, Abe K, Taira T, Chang JW.

N Engl J Med. 2016 Aug 25;375(8):730-9. doi: 10.1056/NEJMoa1600159.

34.

Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation.

Garcia-Borreguero D, Silber MH, Winkelman JW, Högl B, Bainbridge J, Buchfuhrer M, Hadjigeorgiou G, Inoue Y, Manconi M, Oertel W, Ondo W, Winkelmann J, Allen RP.

Sleep Med. 2016 May;21:1-11. doi: 10.1016/j.sleep.2016.01.017. Epub 2016 Feb 23.

35.

Efficacy of gabapentin enacarbil in adult patients with severe primary restless legs syndrome.

Lee DO, Buchfuhrer MJ, Garcia-Borreguero D, Avidan AY, Ahmed M, Hays R, Ondo WG, Jaros MJ, Kim R, Shang G.

Sleep Med. 2016 Mar;19:50-6. doi: 10.1016/j.sleep.2015.11.002. Epub 2015 Nov 14.

PMID:
27198947
36.

OnabotulinumtoxinA and AbobotulinumtoxinA Dose Conversion: a Systematic Literature Review.

Dashtipour K, Chen JJ, Espay AJ, Mari Z, Ondo W.

Mov Disord Clin Pract. 2016 Mar-Apr;3(2):109-115. Epub 2015 Oct 12.

37.

Essential Tremor: What We Can Learn from Current Pharmacotherapy.

Ondo W.

Tremor Other Hyperkinet Mov (N Y). 2016 Mar 4;6:356. doi: 10.7916/D8K35TC3. eCollection 2016. Review.

38.

A novel scale to assess psychosis in patients with parkinson's disease.

Ondo WG, Sarfaraz S, Lee M.

J Clin Mov Disord. 2015 Dec 1;2:17. doi: 10.1186/s40734-015-0024-5. eCollection 2015.

39.

Effect of prior exposure to dopamine agonists on treatment with gabapentin enacarbil in adults with moderate-to-severe primary restless legs syndrome: pooled analyses from 3 randomized trials.

Ondo WG, Hermanowicz N, Borreguero DG, Jaros MJ, Kim R, Shang G.

J Clin Mov Disord. 2015 Mar 30;2:9. doi: 10.1186/s40734-015-0018-3. eCollection 2015.

41.

Clinical characteristics of leg restlessness in Parkinson's disease compared with idiopathic Restless Legs Syndrome.

Zhu XY, Liu Y, Zhang XJ, Yang WH, Feng Y, Ondo WG, Tan EK, Wu YC.

J Neurol Sci. 2015 Oct 15;357(1-2):109-14. doi: 10.1016/j.jns.2015.07.008. Epub 2015 Jul 9.

PMID:
26189051
42.

The impact of DaTscan in the diagnosis of Parkinson disease.

Gayed I, Joseph U, Fanous M, Wan D, Schiess M, Ondo W, Won KS.

Clin Nucl Med. 2015 May;40(5):390-3. doi: 10.1097/RLU.0000000000000766.

PMID:
25783511
43.

Role of apomorphine in the treatment of Parkinson's disease.

Boyle A, Ondo W.

CNS Drugs. 2015 Feb;29(2):83-9. doi: 10.1007/s40263-014-0221-z. Review.

PMID:
25676564
44.

Response to "Shaky legs: more than meets the eyes (or ears)".

Ondo W.

Parkinsonism Relat Disord. 2015 Feb;21(2):163. doi: 10.1016/j.parkreldis.2014.10.024. Epub 2014 Nov 1. No abstract available.

PMID:
25466407
45.

Does idiopathic restless legs syndrome delay onset and reduce severity of Parkinson's disease: a pilot study.

Dragan EM, Chen Z, Ondo WG.

Int J Neurosci. 2015;125(7):526-30. doi: 10.3109/00207454.2014.987771. Epub 2014 Dec 18.

PMID:
25405536
46.

Restless legs syndrome: pathophysiology and treatment.

Ondo WG.

Curr Treat Options Neurol. 2014 Nov;16(11):317. doi: 10.1007/s11940-014-0317-2.

PMID:
25238731
47.

IPX066 , a mixed immediate/sustained-release levodopa preparation for Parkinson's disease.

Ondo W.

Expert Opin Pharmacother. 2014 Oct;15(14):2081-5. doi: 10.1517/14656566.2014.950224. Epub 2014 Aug 22. Review.

PMID:
25146967
48.

Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria--history, rationale, description, and significance.

Allen RP, Picchietti DL, Garcia-Borreguero D, Ondo WG, Walters AS, Winkelman JW, Zucconi M, Ferri R, Trenkwalder C, Lee HB; International Restless Legs Syndrome Study Group.

Sleep Med. 2014 Aug;15(8):860-73. doi: 10.1016/j.sleep.2014.03.025. Epub 2014 May 17.

PMID:
25023924
49.

Differentiating nocturnal leg cramps and restless legs syndrome.

Rana AQ, Khan F, Mosabbir A, Ondo W.

Expert Rev Neurother. 2014 Jul;14(7):813-8. doi: 10.1586/14737175.2014.927734. Epub 2014 Jun 14. Review.

PMID:
24931546
50.

Sleep/wake problems in Parkinson's disease: pathophysiology and clinicopathologic correlations.

Ondo WG.

J Neural Transm (Vienna). 2014 Aug;121 Suppl 1:S3-13. doi: 10.1007/s00702-014-1239-6. Epub 2014 May 25. Review.

PMID:
24858728

Supplemental Content

Support Center